IRIDEX Corporation characterized its second quarter results as a financial inflection point, marking the achievement of positive cash flow after a two-year initiative focused on transforming its cost structure and enhancing working capital management practices.
The company is currently undertaking a headquarters relocation project aimed at optimizing its infrastructure and improving long-term operational efficiency. This move requires a new registration process globally and necessitates inventory blackout periods that management is addressing through proactive inventory builds. Management anticipates a temporary reduction in cash on hand through the remainder of 2026 due to the safety stock inventory builds required to navigate these regulatory blackout periods during the relocation.
Glaucoma performance demonstrated strength with a 35% increase in Cyclo G6 probe volume, which management attributed to targeted physician engagement efforts via MedScout and positive developments from Medicare Local Coverage Determinations. International glaucoma growth was supported by distributor stocking in Japan and Brazil ahead of planned business transitions. Management expects low-double-digit growth for glaucoma probes to continue through the second half of the year. Retina revenue experienced declines attributed to temporary commercial transitions and regulatory factors internationally rather than fundamental product demand issues. Management expects retina performance to return to low-single-digit growth in the second half of 2026, supported by the American Academy of Ophthalmology meeting and annual promotional programs.
Gross margins were impacted by cost pressures and softer retina systems margins, though management expects ongoing shifts to third-party contract manufacturers to drive improvements in 2027. Operating expenses decreased 5% year-over-year, primarily due to the successful transfer of administrative functions to lower-cost structures. The company reaffirmed full-year 2026 revenue guidance of $51 million to $53 million, assuming pro forma growth of 1% to 5% when excluding Middle East revenue, which remains a persistent headwind due to regional conflict.
Looking ahead, management expects PASCAL systems to secure European MDR approval in the first half of 2027, anticipated to unlock meaningful demand in the EMEA region. Working capital is projected to become a cash tailwind in 2027 as elevated inventory levels are worked down following the completion of manufacturing transitions. Q4 is historically the company’s largest quarter, and management expects this seasonal trend to persist in 2026.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI